Exploration of potential novel drug targets for diabetic retinopathy by plasma proteome screening

Weichen Yuan,Wei Xu,Xin Xu,Bo Qu,Fangkun Zhao

DOI: https://doi.org/10.1038/s41598-024-62069-0

IF: 4.6

2024-05-24

Scientific Reports

Abstract:The aim of this study is to identify novel potential drug targets for diabetic retinopathy (DR). A bidirectional two-sample Mendelian randomization (MR) analysis was performed using protein quantitative trait loci (pQTL) of 734 plasma proteins as the exposures and clinically diagnosed DR as the outcome. Genetic instruments for 734 plasma proteins were obtained from recently published genome-wide association studies (GWAS), and external plasma proteome data was retrieved from the Icelandic Decoding Genetics Study and UK Biobank Pharma Proteomics Project. Summary-level data of GWAS for DR were obtained from the Finngen Consortium, comprising 14,584 cases and 202,082 population controls. Steiger filtering, Bayesian co-localization, and phenotype scanning were used to further verify the causal relationships calculated by MR. Three significant ( p < 6.81 × 10 −5 ) plasma protein-DR pairs were identified during the primary MR analysis, including CFH (OR = 0.8; 95% CI 0.75–0.86; p = 1.29 × 10 −9 ), B3GNT8 (OR = 1.09; 95% CI 1.05–1.12; p = 5.9 × 10 −6 ) and CFHR4 (OR = 1.11; 95% CI 1.06–1.16; p = 1.95 × 10 −6 ). None of the three proteins showed reverse causation. According to Bayesian colocalization analysis, CFH (coloc.abf-PPH4 = 0.534) and B3GNT8 (coloc.abf-PPH4 = 0.638) in plasma shared the same variant with DR. All three identified proteins were validated in external replication cohorts. Our research shows a cause-and-effect connection between genetically determined levels of CFH, B3GNT8 and CFHR4 plasma proteins and DR. The discovery implies that these proteins hold potential as drug target in the process of developing drugs to treat DR.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to identify new potential drug targets for diabetic retinopathy (DR). The study employs bidirectional two-sample Mendelian randomization (MR) analysis, using protein quantitative trait loci (pQTL) of 734 plasma proteins as exposure factors and clinically diagnosed DR as the outcome variable. Researchers obtained genetic instruments for the 734 plasma proteins from recently published genome-wide association studies (GWAS) and retrieved external plasma proteomics data from the Icelandic deCODE genetics study and the UK Biobank pharmaceutical proteomics project. Additionally, summary-level GWAS data for DR, including 14,584 cases and 202,082 controls, were obtained from the Finnish FinnGen consortium.

In the initial MR analysis, the study identified three significant (p < 6.81 × 10^-5) plasma protein-DR pairs: complement factor H (CFH), β-3-N-acetylglucosaminyltransferase 8 (B3GNT8), and complement factor H-related protein 4 (CFHR4). These proteins have a causal relationship with DR, suggesting they may be potential drug targets for treating DR. Furthermore, these causal relationships were validated through Bayesian colocalization analysis. Ultimately, these findings provide important clues for developing new treatments for DR.